Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
前收盘价
US$13.80
+US$0.22 · +1.62%
盘中时间采用ET。市场数据可能有所延迟。
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
日内区间
当前US$13.80
52周区间
当前US$13.80
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
7
估值过高
情绪
50
多空交织
风险
63
高风险
动量
26
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
日内区间
当前US$13.80
52周区间
当前US$13.80
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3.6万 USD | 6.1万 USD | 13万 USD | 8468.3万 USD | 1065万 USD |
| 销货成本 | 1153.9万 USD | — | — | — | — |
| 毛利 | −1150.3万 USD | 6.1万 USD | 13万 USD | 8468.3万 USD | 1065万 USD |
| 研究与开发 | 1.59亿 USD | 1.72亿 USD | 1.83亿 USD | 1.59亿 USD | 1.39亿 USD |
| 销售、一般及管理费用 | 4513.5万 USD | 5204.1万 USD | 6698.3万 USD | 1.17亿 USD | 8905.7万 USD |
| 营业费用 | 1.92亿 USD | 3.59亿 USD | 2.47亿 USD | 2.72亿 USD | 2.25亿 USD |
| 利息收入 | 1308万 USD | 2406.8万 USD | 2345.3万 USD | 705.3万 USD | 116.5万 USD |
| 折旧和摊销 | 1153.9万 USD | 1963.1万 USD | 2025万 USD | 1802万 USD | 1362.4万 USD |
| 营业利润 | −2.04亿 USD | −3.59亿 USD | −2.47亿 USD | −1.87亿 USD | −2.15亿 USD |
| 净利润 | −2.74亿 USD | −3.43亿 USD | −2.35亿 USD | −1.83亿 USD | −2.5亿 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$39.50
上涨空间 186.23%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI525.87万0.00%6893亿 USD0.03%US$340.02-3.52%
iShares Russell 2000 ETFIWM322.32万0.00%715.37亿 USD0.19%US$256.61-2.88%
Vanguard Extended Market ETFVXF138.92万0.00%302亿 USD0.05%US$211.44-3.21%
iShares Russell 2000 Value ETFIWN123.44万0.01%130.46亿 USD0.24%US$198.84-2.08%
iShares Biotechnology ETFIBB81.93万0.01%105.27亿 USD0.44%US$199.54-2.05%
Schwab U.S. Small-Cap ETFSCHA75.05万0.00%204.47亿 USD0.03%US$30.51-2.83%
Vanguard Russell 2000 ETFVTWO55.44万0.00%168亿 USD0.06%US$103.76-2.76%
iShares Micro-Cap ETFIWC35.05万0.03%10.88亿 USD0.60%US$157.87-3.19%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Value ETFIWN
iShares Biotechnology ETFIBB
Schwab U.S. Small-Cap ETFSCHA
Vanguard Russell 2000 ETFVTWO
iShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。